v3.25.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Net sales $ 1,076,881 $ 1,360,736
Cost of goods sold [1] 920,582 1,321,798
Gross profit 156,299 38,938
Selling, general and administrative expenses 123,502 161,376
Restructuring charges and asset write-offs (1,063) 33,536
Research and development expenses 14,099 23,532
Operating profit (loss) 19,761 (179,506)
Interest and financing expenses (48,977) (37,969)
Other income, net 10,250 49,901
Loss before income taxes and equity in net income of unconsolidated investments (18,966) (167,574)
Income tax benefit (3,978) (3,721)
Loss before equity in net income of unconsolidated investments (14,988) (163,853)
Equity in net income of unconsolidated investments (net of tax) 64,286 180,500
Net income 49,298 16,647
Net income attributable to noncontrolling interests (7,950) (14,199)
Net income attributable to Albemarle Corporation 41,348 2,448
Mandatory convertible preferred stock dividends (41,688) (11,584)
Net loss attributable to Albemarle Corporation common shareholders $ (340) $ (9,136)
Basic loss per share attributable to common shareholders (in dollars per share) $ 0.00 $ (0.08)
Diluted loss per share attributable to common shareholders (in dollars per share) $ 0.00 $ (0.08)
Weighted-average common shares outstanding - basic (in shares) 117,603 117,451
Weighted-average common shares outstanding - diluted (in shares) 117,603 117,451
[1] Included purchases from related unconsolidated affiliates of $119.8 million and $540.7 million for the three-month periods ended March 31, 2025 and 2024, respectively.